EchoGo® Amyloidosis
AI-powered screening for cardiac amyloidosis from routine echocardiography
Software · Cloud SaaSCompany source
Company profile
About Ultromics
Ultromics is a cardiovascular AI company that has developed FDA-cleared, clinically validated artificial intelligence solutions for identifying heart failure and cardiac amyloidosis from routine echocardiography. The company's flagship products, EchoGo® Heart Failure and EchoGo® Amyloidosis, analyze standard apical four-chamber echo views to detect HFpEF and screen for cardiac amyloidosis—two severely underdiagnosed cardiovascular conditions. Founded by Ross Upton (CEO) and Professor Paul Leeson (Chief Medical Officer), Ultromics has built its technology through collaborations with leading research institutions including Mayo Clinic, University of Oxford, and University of Chicago Medicine. The platform is designed to integrate directly into existing PACS, CVIS, and EMR systems through standard DICOM workflows, requiring no changes to scanning protocols or clinical workflows. Results are typically delivered within 20 minutes of study acquisition. Ultromics has achieved FDA 510(k) clearance and Breakthrough Device Designation for both products, with EchoGo® Heart Failure receiving CPT Category III code 0932T from CMS for reimbursement. The company is live in top U.S. hospitals including University Hospitals, City of Hope, University of Wisconsin, and UT Southwestern. Ultromics maintains healthcare compliance certifications including HIPAA, ISO 27001, ISO 13485, and Cyber Essentials. The company works with industry partners including Johnson & Johnson Innovative Medicine and Pfizer, and collaborates with government organizations including the FDA TAP Program, FNIH, and the American Society of Echocardiography.
Company description Ultromics official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Work at Ultromics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- ATTR-CM
- Cardiac Amyloidosis
- Diastolic Dysfunction
- Heart Failure with Preserved Ejection Fraction (HFpEF)
Who it serves
- Academic Medical Centers
- Cardiology Departments
- Health Systems
- Hospital Echo Labs
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: CVIS, EMR, Fujifilm Synapse, PACS.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
FDA 510(k) clearance for both products. FDA Breakthrough Device Designation. CMS CPT Category III code 0932T assignment. Live deployment in top U.S. hospitals. Integration with Fujifilm Synapse. Publications in JACC Advances (2023) and European Heart Journal (2025).
Partnerships
Recorded partners
- American Society of Echocardiography
- FDA TAP Program
- FNIH
- Fujifilm
- Johnson & Johnson Innovative Medicine
- Mayo Clinic
- Microsoft
- Pfizer
- University of Chicago Medicine
- University of Oxford
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
EchoGo® Heart Failure
AI-powered detection for HFpEF from routine echocardiography
Software · Cloud SaaSCompany source
EchoGo® Platform
Integrated workflow platform delivering AI insights for heart failure detection
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Economic Evaluation of the Use of Artificial Intelligence in Stress Echocardiography: Cost-Consequence and Cost-Effectiveness Analysis.Value in health regional issues · Jun 17, 2026
Diagnostic Performance Evaluation of Clinical and Artificial Intelligence Risk Models in Patients Referred for Cardiac Amyloidosis Testing.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · May 13, 2026
Invasive haemodynamic validation of an artificial intelligence echocardiographic tool for detecting heart failure with preserved ejection fraction.ESC heart failure · Mar 3, 2026
Heat thermotherapy to improve cardiovascular function and cardiometabolic health: A systematic review and meta-analysis.Experimental physiology · Oct 30, 2025
Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.European heart journal · Oct 22, 2025
DeepSPV: A deep learning pipeline for 3D spleen volume estimation from 2D ultrasound images.Medical image analysis · Oct 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
EchoGo Amyloidosis (1.0)K240860 · 510k · Nov 15, 2024
EchoGo Heart Failure (2.0)K240013 · 510k · Sep 23, 2024
EchoGo Core (2.0)K213275 · 510k · Dec 20, 2021
EchoGo ProK201555 · 510k · Dec 18, 2020
EchoGo CoreK191171 · 510k · Nov 13, 2019
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Early identification of HFpEF
From routine echocardiograms, including borderline or indeterminate cases
Cardiac amyloidosis screening
Identifying patients suggestive of cardiac amyloidosis years earlier in disease progression
Results within 20 minutes
Automated analysis delivered into existing clinical systems
Incremental reimbursement
CPT Category III code 0932T for EchoGo® Heart Failure
City of Hope
Using Ultromics technology in echo workflows to help clinical teams flag HFpEF and cardiac amyloidosis to support reporting and assessments
Mayo Clinic
Research collaboration to advance cardiovascular science and clinical validation of Ultromics AI models
Case study showed EchoGo Amyloidosis could have identified cardiac amyloidosis 4 years earlier when LVEF was preserved at 50-55% instead of deteriorated to 30-35%
University Hospitals
Using Ultromics technology to support heart failure assessment and identify patients with HFpEF and cardiac amyloidosis in clinical practice
Physicians reported that Ultromics helped identify patients with HFpEF and cardiac amyloidosis, including when findings are subtle or inconclusive
University of Chicago Medicine
Using Ultromics AI to identify patients with HFpEF and cardiac amyloidosis from routine echocardiograms and research collaboration
University of Oxford
Research collaboration to advance cardiovascular science and develop AI models
University of Wisconsin
Using Ultromics technology in echo workflows to help clinical teams flag HFpEF and cardiac amyloidosis to support reporting and assessments
Unnamed U.S. Hospital
Case study: 70-year-old male with multiple hospitalizations and inconclusive evaluations over 4 years. EchoGo Amyloidosis flagged cardiac amyloidosis in 2025, retrospective analysis showed it would have flagged the condition in 2021
Could have enabled diagnosis 4 years earlier when LVEF was preserved at 50-55% instead of deteriorated to 30-35%
UT Southwestern
Using Ultromics technology in echo workflows to help clinical teams flag HFpEF and cardiac amyloidosis to support reporting and assessments
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Ross Upton
Founder and Chief Executive Officer
Ross Upton
Founder and Chief Executive Officer
Paul Leeson
Founder and Chief Medical Officer
Prof. Paul Leeson
Founder and Chief Medical Officer
John Russell
Chairman
John Russell
Chairman
Roger Owens
Chief Commercial Officer
Roger Owens
Chief Commercial Officer
06 · Company updates
Updates from Ultromics
Recent articles published on Ultromics's official website.
American Heart Association AI Assessment Lab Report Finds Ultromics’ EchoGo® Heart Failure May Identify HFpEF Earlier Than Standard Care
Read on UltromicsUltromics Study Shows AI Could Improve Early Detection of Cardiac Amyloidosis
Read on UltromicsUltromics Study Shows AI Could Improve Early Detection of Cardiac Amyloidosis
Read on Ultromics07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.